Date | Price Target | Rating | Analyst |
---|
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
3 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
D - Nautilus Biotechnology, Inc. (0001808805) (Filer)
8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
425 - ARYA Sciences Acquisition Corp III (0001808805) (Subject)
8-K - ARYA Sciences Acquisition Corp III (0001808805) (Filer)
8-K - ARYA Sciences Acquisition Corp III (0001808805) (Filer)
425 - ARYA Sciences Acquisition Corp III (0001808805) (Subject)
4 - ARYA Sciences Acquisition Corp III (0001808805) (Issuer)
424B3 - ARYA Sciences Acquisition Corp III (0001808805) (Filer)
EFFECT - ARYA Sciences Acquisition Corp III (0001808805) (Filer)
10-Q - ARYA Sciences Acquisition Corp III (0001808805) (Filer)
SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13G - ARYA Sciences Acquisition Corp III (0001808805) (Subject)
SC 13G - ARYA Sciences Acquisition Corp III (0001808805) (Subject)
SIOUX FALLS, S.D., July 8, 2021 /PRNewswire-PRWeb/ -- MarketBeat, a leading source for stock market data and research tools, has published a monthly list ranking The 10 Stocks with the Most Insider Buying in June 2021. An insider trade occurs when a company executive or individual who has non-public information about a company buys or sells shares of that company's stock. The level of stock that insiders are buying is a potential indicator of the stock's future performance. The MarketBeat editorial team compiled the 10 stocks with the most insider trading by utilizing the company's Stocks with the Most Insider Buying Report. For stocks with the most insider buying, software companies and s
Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021Publicly traded company renamed Nautilus Biotechnology, Inc.Common stock commences trading under ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021Gross proceeds from this transaction to Nautilus totaled approximately $345 million, combining approximately $145 million of funds held in Arya III’s trust account and a concurrent PIPE financing of $200 million SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis pla
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III ("ARYA") (NASDAQ:ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, ARYA is strongly encouraging that shareholders attend the extraordinary general meeting of its shareholders on June 8, 2021 at 9:00 a.m., New York City Time (the "General Meeting") remotely by teleconference rather than in person. The purpose of the General Meeting is to vote on certain proposals relating to the previously announced Business Combination Agreement, dated as of February 7, 2021 (the "Business
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the appointment of Matt Murphy, Esq., as General Counsel. Mr. Murphy brings more than 25 years of experience in senior legal counsel roles for companies on the cutting edge of life sciences technologies with specialization in biotechnology and diagnostics. He was previously the Vice President and General Counsel for 10x Genomics and Vice President of Intellectual Property and General Counsel for Pacific Biosciences. Prior to joining Nautilus, Mr. Murphy advised a wide range of leading tec
SEATTLE & NEW YORK--(BUSINESS WIRE)--Nautilus Biotechnology, Inc. ("Nautilus Biotechnology" or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III (Nasdaq: ARYA) (“Arya III”), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Arya III will redomicile as a Delaware corporation, be renamed Nautilus Biotechnology, Inc. and its common stock is expected to be listed on Nasdaq under the ticker symbol “NAUT” (the “Combined Company”). In addit